Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 23/7/2018
SIETES contiene 92430 citas

 
 
 1 a 20 de 339 siguiente >>
Presentar resultados
Seleccionar todas
3.Enlace a cita original Cita con resumen
Johansen ME. Gabapentinoid use in the United States 2002 rhrough 2015. JAMA Intern Med 2018;178:febrero. [Ref.ID 102530]
4. Cita con resumen
Johansen ME. Gabapentinoid use in the United States 2002 through 2015. JAMA Intern Med 2018:2 de enero. [Ref.ID 102440]
5. Cita con resumen
Bjørk M, Riedel B, Spiqset O, Veiby G, Kolstad E, Daltveit AK, Gilhus NE. Association of folic acid supplementation during pregnancy with the risk of autistic traits in children exposed to antiepileptic drugs In utero. JAMA Neurology 2017:26 de diciembre. [Ref.ID 102193]
6. Cita con resumen
Peckham AM, Fairman KA, Sclar DA. Call for increased pharmacovigilance of gabapentin. BMJ 2017;359:j5456. [Ref.ID 102156]
7. Cita con resumen
Gomes T, Juurlink DN, Antoniou T, Mamdani MM, Paterson JM, van den Brink W. Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case–control study. PLOS Medicine 2017:3 de octubre. [Ref.ID 102112]
8. Cita con resumen
Pinto RZ, Verwoerd AJH, Koes BW. Which pain medications are effective for sciatica (radicular leg pain)?. BMJ 2017;359:j4248. [Ref.ID 102095]
9. Cita con resumen
Ho JM-W, Macdonald EM, Luo J, Gomes T, Antoniou T, Mamdani MM, Juurlink DN. Pregabalin and heart failure: A population-based study. Pharmacoepidemiol Drug Saf 2017;26:1087-92. [Ref.ID 102064]
10. Cita con resumen
Buttram ME, Kurtz SP, Dart RC, Margolin ZR. Law enforcement-derived data on gabapentin diversion and misuse, 2002-2015: diversion rates and qualitative research findings. Pharmacoepidemiol Drug Saf 2017;26:1083-7. [Ref.ID 102063]
11. Cita con resumen
Zaccara G, Giovannelli F, Giorgi FS, Franco V, Gasparini S, Tacconi FM. Do antiepileptic drugs increase the risk of infectious diseases? A meta-analysis of placebo-controlled studies. Br J Clin Pharmacol 2017;83:1873-9. [Ref.ID 102027]
13. Cita con resumen
Zaccara G, Giovannelli F, Giorgi FS, Franco V, Gasparini S, Benedetto U. Tolerability of new antiepileptic drugs: a network meta-analysis. Eur J Clin Pharmacol 2017;73:811-7. [Ref.ID 101994]
14.Tiene citas relacionadas Cita con resumen
15. Cita con resumen
Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]
16. Cita con resumen
Anónimo. Daclizumab for MS. Drug Ther Bull 2017;55:18-21. [Ref.ID 101403]
17. Cita con resumen
Anónimo. Drugs for menopausal symptoms. Med Lett Drugs Ther 2016;58:142-5. [Ref.ID 100946]
18. Cita con resumen
Smith JA, Woodcock A. Chronic cough. N Engl J Med 2016;375:1544-51. [Ref.ID 100909]
19.Tiene citas relacionadas Cita con resumen
Smith RV, Havens JR, Walsh SL. Gabapentin misuse, abuse and diversion: a systematic review. Addiction 2016;111:1160-74. [Ref.ID 100800]
20. Cita con resumen
Baftiu A, Landmark CJ, Rusten IR, Feet SA, Johannessen SI, Larsson PG. Changes in utilisation of antiepileptic drugs in epilepsy and non-epilepsy disorders - A pharmacoepidemiological study and clinical implications. Eur J Clin Pharmacol 2016;72:1245-54. [Ref.ID 100799]
Seleccionar todas
 
 1 a 20 de 339 siguiente >>